Abstract
Gastritis caused byHelicobacter pylori (HP) is common in patients with nonulcer dyspepsia (NUD), but an etiologic relationship between the histologic lesion and clinical symptoms is unproven. HP is inhibited by bismuth subsalicylate (BSS), a traditional remedy for dyspeptic complaints. The aim of this study was to assess the short- and long-term effects of BSS on HP, gastritis, and symptoms in patients with NUD. One hundred twenty-six patients with NUD who were shown to be infected withH. pylori (HP+) were enrolled. There was a two-week placebo run-in period to eliminate placebo responders. Fifty patients remained symptomatic and were randomly assigned to therapy with either BSS liquid or a matching placebo. EGD, biopsy, and clinical evaluations were performed at entry, at week 5 (end of therapy), at week 9 (four weeks after therapy), or at time of symptomatic relapse. Twenty-seven patients received placebo and 23 patients received BSS. BSS suppressedH. pylori in 15/23 patients (65%) and eradicated it in one patient, whereas the placebo had no effect onH. pylori. Gastritis improved during therapy with BSS but relapsed by week 9. There was no significant change in level of dyspeptic symptoms during or after treatment, although one month after the end of treatment, the patients in the BSS group consistently had lower symptom scores and fewer symptomatic days for all symptoms measured. The study confirms that BSS given for three weeks suppresses but does not usually eradicateH. pylori. Such short-term suppression ofH. pylori heals gastritis but does not result in clinical improvement.
Similar content being viewed by others
References
Barbara L, Camilleri M, Corinaldesi R Crean GP, Heading RC, Johnson AG, Malagelada JR, Stanghellini V, Wienbeck M: Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci 34(8):1272–1276, 1989
Colin Jones DG:Campylobacter pylori. An advance in understanding of dyspepsia and gastritis. J Clin Gastroenterol 11:S39-S42, 1989
Talley NJ, Phillips SF: Non-ulcer dyspepsia: Potential causes and pathophysiology. Ann Intern Med 108(6):865–879, 1988
Pettross CW, Appleman MD, Cohen H, Valenzuela JE, Chandrasoma P, Laine LA: Prevalence ofCampylobacter pylori and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms. Dig Dis Sci 33:649–653, 1988
Rokkas T, Pursey C, Uzoechina E, et al:Campylobacter pylori and non-ulcer dyspepsia. Am J Gastroenterol 82:1149–1152, 1987
Kang JY, Wee A, Math MV et al:Helicobacter pylori and gastritis in patients with peptic ulcer and non-ulcer dyspepsia: Ethnic differences in Singapore. Gut 31:850–853, 1990
Strauss RM, Wang TC, Kelsey PB et al: Association ofHelicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med 89:464–469, 1990
Dye KR, Marshall BJ, Frierson HF, Barrett LJ, Guerrant RL, McCallum RW: Is CLOtest alone adequate to diagnoseCampylobacter pylori? Am J Gastroenterol 83:1032, 1988 (abstract)
Gad A, Dobrilla G:Campylobacter pylori and non-ulcer dyspepsia. 1. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. Scand J Gastroenterol Suppl 167:39–43, 1989
Britt DP, Barakat MH, Tungekar MF, et al: Helicobacter pylori in dyspeptic patients in Kuwait. J Clin Pathol 43:987–991, 1990
Tytgat GN, Rauws EA, De Koster E:Campylobacter pylori. Scand J Gastroenterol Suppl 155:68–81, 1988
Marshall BJ: Should we now, routinely, be examining gastric biopsies forCampylobacter pylori? Gastric mucosal biopsy: An essential investigation in patients with dyspepsia. Am J Gastroenterol 83:479–481, 1988
Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH: The antibacterial action of bismuth in relation toCampylobacter pyloridis colonization and gastritis. Digestion 37(suppl 2):16–30, 1987
Talley NJ:Campylobacter pylori-associated gastritis. Is antibiotic therapy now justified. J Clin Gastroenterol 10:10–12, 1988
Dooley CP, Cohen H: The clinical significance ofCampylobacter pylori. Ann Intern Med 108:70–79, 1988
Lanza FL, Skoglund ML, Rack MF, Yardley JH: The effect of bismuth subsalicylate on the histologic gastritis seen withCampylobacter pylori: A placebo-controlled, randomized study. Am J Gastroenterol 84:1060–1064, 1989
McNulty CA: Bismuth subsalicylate in the treatment of gastritis due toCampylobacter pylori. Rev Infect Dis 12:S94-S98, 1990
Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow E: Rapid urease test in the management ofCampylobacter pyloridis-associated gastritis. Am J Gastroenterol 82(3):200–210, 1987
McNulty CA, Gearty JC, Crump B, et al:Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res) 293:645–649, 1986
Rokkas T, Pursey C, Uzoechina E, et al: Non-ulcer dyspepsia and short term De-Nol therapy: A placebo controlled trial with particular reference to the role ofCampylobacter pylori. Gut 29:1386–1391, 1988
Lambert JR, Dunn K, Borromeo M, Korman MG, Hansky J:Campylobacter pylori—a role in non-ulcer dyspepsia. Scand J Gastroenterol Suppl 160:7–13, 1989
Kang JY, Tay HH, Wee A, Guan R, Math MV, Yap I: Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 31:476–480, 1990
Loffeld RJ, Potters HV, Stobberingh E, Flendrig JA, van Spreeuwel JP, Arends JW: Campylobacter associated gastritis in patients with non-ulcer dyspepsia: A double blind placebo controlled trial with colloidal bismuth subcitrate. Gut 30:1206–1212, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marshall, B.J., Valenzuela, J.E., McCallum, R.W. et al. Bismuth subsalicylate suppression ofHelicobacter pylori in nonulcer dyspepsia: A double-blind placebo-controlled trial. Digest Dis Sci 38, 1674–1680 (1993). https://doi.org/10.1007/BF01303177
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01303177